P/B
—
BridgeBio Pharma
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
$12.8B
Market Cap • 10/9/2026
2019
(7 years)
Founded
2019
(7 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
17,9
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
12,8B
EV
14,6B
EV/Revenue
20,4
EV/EBITDA
-29,5
EV/EBIT
-29,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
1,4%
Total Yield
1,4%
Payout
0%
Retained Earnings
-4,1B
Profitability
Gross Margin
94,4%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
70,9%
Capex/Revenue
0,1%
Capex/D&A
20%
Capex/OCF
-0,2%
SBC/OCF
—
% PPE
1,8%
% Goodwill
0%
ROE
32,8%
ROIC
—
Growth
CAGR Revenue 5Y
62,6%
CAGR Op. Income 5Y
-0,4%
CAGR Net Income 5Y
5,5%
CAGR EPS 5Y
-1,4%
CAGR OCF 5Y
-1,6%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
1,2
Quick Ratio
1,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!